Concerning the following extract, taken from 'Q&A #06 - Geert and John’s email exchange of thought and ideas about the Omicron articles':
‘Continued mass vaccination will only push the evolutionary capacity of SARS-CoV-2 Spike protein beyond the Omicron version’ – allosteric mutations and ADE, remember?
It’s ADE that is going to tip the balance in the wrong and irreversible direction. ADE in vaccinees will provide the virus with exceptional virulence and make it resemble Marek in unvaccinated…this means natural selection against all those whose innate immunity got messed up.
“What I meant is that because of ADE, SARS-CoV-2 will become more virulent and C-19 pathogenicity will be enhanced. The parallel with Marek only applies to the level of virulence, not to the symptomatology. Disease will still be C-19, but much enhanced / exacerbated.”
Re-read from the Omicron article:
“(...)While such natural selection would lead to an eradication of SARS-CoV-2 as innate immunity sterilizes the virus and blocks transmission, the consequences would be unimaginable – the price paid for ending the pandemic by virus eradication is not comparable to the one paid for by generating herd immunity and allowing the virus to enter an endemic state. Those who are enforcing mass vaccination are opting for the former instead of the latter, an act that will be remembered as the deadliest sin ever.”
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.
Email: info@voiceforscienceandsolidarity.org
.svg){kind=small}
